Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ).
Qyuns Therapeutics Co., Ltd. has entered into an exclusive license agreement with Caldera Therapeutics for the global development and commercialization of QX030N, a pre-clinical bispecific antibody for immunologic disorders. This agreement includes a $10 million upfront payment and potential milestone payments up to $545 million, alongside equity interest in Caldera. The partnership is expected to significantly contribute to Qyuns’ business expansion and enhance its market positioning in the biopharmaceutical sector.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative therapeutics. The company is engaged in expanding its global cooperation network and enhancing its pipeline and commercial value through strategic partnerships.
YTD Price Performance: 35.77%
Average Trading Volume: 125,460
Technical Sentiment Signal: Strong Buy
See more data about 2509 stock on TipRanks’ Stock Analysis page.